Volastra Therapeutics, Inc. Interview Guide

Volastra Therapeutics, Inc. is a dynamic clinical-stage oncology biotech company based in New York City, dedicated to pioneering innovative cancer treatments that specifically target chromosomal instability (CIN). Founded in 2019, Volastra has made remarkable strides in its research pipeline, particularly with its two KIF18A inhibitors: VLS-1488, which is set to enter clinical trials in late 2023, and Sovilnesib, expected to re-enter the clinic in 2024. Supported by distinguished venture firms in the US and Europe, along with strategic investments from Eli Lilly, Volastra has forged valuable partnerships with leading oncology organizations and is guided by a highly experienced senior leadership team. The company promotes a culture of continuous learning and innovation, offering extensive opportunities for professional development as it enhances its data capabilities and confronts new challenges in the oncology landscape.